Maintenance therapy comparison for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether adding two medicines (fluzoparib plus apatinib) works better than fluzoparib alone to keep recurrent ovarian, fallopian tube, or primary peritoneal cancer from growing. It targets people whose cancer responded to recent platinum chemotherapy and who previously took a PARP inhibitor as maintenance therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and sign the informed consent to join.
- Your cancer type matches high-grade serous ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or mostly endometrioid tumors (not a mix with small serous/endometrioid parts).
- Your cancer was treated with 2 or 3 prior platinum chemotherapy lines, and the most recent one included platinum.
- Your cancer came back after more than 6 months from the last platinum dose (platinum-sensitive), and you still have a complete or partial response (CR/PR) within 8 weeks of finishing that platinum treatment.
- You previously took a PARP inhibitor as maintenance, for long enough based on whether you have BRCA1/2.
- You can take pills (no major swallowing or absorption problems), and you meet blood/organ health limits (blood counts, liver, kidney, and albumin) checked around screening.
- You must be able to use approved birth control during the study and for 3 months after, and you must not be pregnant when you enroll (for people who can become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (fluzoparib and apatinib) as maintenance therapy after chemotherapy for women with relapsed ovarian cancer. It might help keep the cancer from coming back for those who have already responded well to platinum-based chemo.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This trial tests whether taking fluzoparib (a PARP inhibitor) plus apatinib (a targeted therapy) after initial chemotherapy can help keep advanced ovarian, fallopian tube, or primary peritoneal cancer from coming back. It is for people who have finished their first treatment and are in good overall health.
This study tests two oral medications (Fluzopril and Apatinib) as a maintenance treatment to keep ovarian cancer from growing after initial chemotherapy. It is for women whose cancer returned within 6 months of platinum-based chemo, and who are currently stable after their last chemo cycle.
This trial tests a combination of two oral medications—fluzoparib (a PARP inhibitor) and famitinib (a TKI)—as maintenance therapy to keep advanced ovarian cancer from coming back after successful first-line chemotherapy. It is for women whose cancer responded well to initial platinum-based treatment.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
Hear when a new Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.